Phuturdex › Diseases › Alpha-1-antitrypsin deficiency
Drugs in development · updated 30 October 2026
Alpha-1-antitrypsin deficiency: drugs in development
As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 11 drugs for Alpha-1-antitrypsin deficiency. 11 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Fazirsiran Injection | III | 3 | NCT05677971 |
| BEAM-302 | I–II | 1 | NCT06389877 |
| CTX460 | I–II | 1 | NCT07850076 |
| PM647a | I–II | 1 | NCT07887347 |
| SAR447537 | II | 1 | NCT05897424 |
| TSRA-196 | I–II | 1 | NCT07227207 |
| WVE-006 | I–II | 1 | NCT06405633 |
| AIR-001 | I | 1 | NCT07431112 |
| BMN 349 | I | 1 | NCT06738017 |
| KB408 | I | 1 | NCT06049082 |
| YOLT-202 | Early I | 1 | NCT07193615 |
Sorted by most advanced phase and number of active trials.
All 11 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Digestive System Diseases 36 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Lung disease 104 drugs
- Respiratory disease 57 drugs
- Liver disease 33 drugs
- Genetic disease 33 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D019896 “alpha 1-Antitrypsin Deficiency”. Prevalence: Orphanet.